This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kodama, T. Articles by Okada, Y. Search for Related Content PubMed PubMed Citation Articles by Kodama, T. Articles by Okada, Y.

(American Journal of Pathology. 2004;165:1743-1753.)
© 2004 American Society for Investigative Pathology

ADAM12 Is Selectively Overexpressed in Human Glioblastomas and Is Associated with Glioblastoma Cell Proliferation and Shedding of Heparin-Binding Epidermal Growth Factor

Takahide Kodama^*, Eiji Ikeda^*, Aiko Okada^*, Takashi Ohtsuka^*, Masayuki Shimoda^*, Takayuki Shiomi^*, Kazunari Yoshida, Mitsutoshi Nakada, Eiko Ohuchi and Yasunori Okada^*

From the Departments of Pathology^* and Neurosurgery, School of Medicine, Keio University, Tokyo; the Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa; and Daiichi Fine Chemical Company, Limited, Takaoka, Japan

ADAMs (a disintegrin and metalloproteinases) are multifunctional molecules involved in cell-cell fusion, cell adhesion, membrane protein shedding, and proteolysis. In the present study, we examined the mRNA expression of 13 different ADAM species with putative metalloproteinase activity in human astrocytic tumors, nonneoplastic brain tissues, and other intracranial tumors by reverse transcriptase-polymerase chain reaction, and found that prototype membrane-anchored ADAM12 (ADAM12m) is predominantly expressed in glioblastomas. Real-time quantitative polymerase chain reaction indicated that the expression level of ADAM12m is remarkably at least 5.7-fold higher in glioblastomas (n = 16) than in nonneoplastic brain tissues (n = 6), low grade (n = 7) and anaplastic astrocytic tumors (n = 9) (P < 0.05 for each group), and intracranial neurinomas (n = 5) (P < 0.01). In situ hybridization showed that glioblastoma cells are responsible for the gene expression. By immunohistochemistry, ADAM12m was predominantly immunolocalized on the cell membranes of glioblastoma cells. Immunoblotting analysis demonstrated that ADAM12m is expressed as an activated N-glycosylated form of 90 kd in glioblastoma tissues. There was a direct correlation between the mRNA expression levels of ADAM12m and proliferative activity (MIB1-positive cell index) of gliomas (r = 0.791, P < 0.0001; n = 32). Protein bands consistent with the soluble form of heparin-binding epidermal growth factor, a substrate of ADAM12m, were observed by immunoblotting in glioblastoma samples with the ADAM12m expression, and inhibited by treatment with ADAM inhibitor of the glioblastomas. These data demonstrate for the first time that among the 13 different ADAM species, ADAM12m is highly expressed in human glioblastomas, and suggest the possibility that ADAM12m plays a role in the prominent proliferation of the glioblastomas through shedding of heparin-binding epidermal growth factor.

This article has been cited by other articles:

				C. Estrella, N. Rocks, G. Paulissen, F. Quesada-Calvo, A. Noel, E. Vilain, P. Lassalle, I. Tillie-Leblond, D. Cataldo, and P. Gosset Role of A Disintegrin And Metalloprotease-12 in Neutrophil Recruitment Induced by Airway Epithelium Am. J. Respir. Cell Mol. Biol., October 1, 2009; 41(4): 449 - 458. [Abstract] [Full Text] [PDF]

				P. H. Huang, A. M. Xu, and F. M. White Oncogenic EGFR Signaling Networks in Glioma Sci. Signal., September 8, 2009; 2(87): re6 - re6. [Abstract] [Full Text] [PDF]

				C. Selvais, H. P. Gaide Chevronnay, P. Lemoine, S. Dedieu, P. Henriet, P. J. Courtoy, E. Marbaix, and H. Emonard Metalloproteinase-Dependent Shedding of Low-Density Lipoprotein Receptor-Related Protein-1 Ectodomain Decreases Endocytic Clearance of Endometrial Matrix Metalloproteinase-2 and -9 at Menstruation Endocrinology, August 1, 2009; 150(8): 3792 - 3799. [Abstract] [Full Text] [PDF]

				K. Bourd-Boittin, H. Le Pabic, D. Bonnier, A. L'Helgoualc'h, and N. Theret RACK1, a New ADAM12 Interacting Protein: CONTRIBUTION TO LIVER FIBROGENESIS J. Biol. Chem., September 19, 2008; 283(38): 26000 - 26009. [Abstract] [Full Text] [PDF]

				C. Frohlich, R. Albrechtsen, L. Dyrskjot, L. Rudkjaer, T. F. Orntoft, and U. M. Wewer Molecular Profiling of ADAM12 in Human Bladder Cancer Clin. Cancer Res., December 15, 2006; 12(24): 7359 - 7368. [Abstract] [Full Text] [PDF]

				Y. Mitsui, S. Mochizuki, T. Kodama, M. Shimoda, T. Ohtsuka, T. Shiomi, M. Chijiiwa, T. Ikeda, M. Kitajima, and Y. Okada ADAM28 Is Overexpressed in Human Breast Carcinomas: Implications for Carcinoma Cell Proliferation through Cleavage of Insulin-like Growth Factor Binding Protein-3. Cancer Res., October 15, 2006; 66(20): 9913 - 9920. [Abstract] [Full Text] [PDF]

				G. Eisele, J. Wischhusen, M. Mittelbronn, R. Meyermann, I. Waldhauer, A. Steinle, M. Weller, and M. A. Friese TGF-{beta} and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells Brain, September 1, 2006; 129(9): 2416 - 2425. [Abstract] [Full Text] [PDF]

				U. M. Wewer, M. Morgelin, P. Holck, J. Jacobsen, M. C. Lydolph, A. H. Johnsen, M. Kveiborg, and R. Albrechtsen ADAM12 Is a Four-leafed Clover: THE EXCISED PRODOMAIN REMAINS BOUND TO THE MATURE ENZYME J. Biol. Chem., April 7, 2006; 281(14): 9418 - 9422. [Abstract] [Full Text] [PDF]

				M. Kveiborg, C. Frohlich, R. Albrechtsen, V. Tischler, N. Dietrich, P. Holck, P. Kronqvist, F. Rank, A. M. Mercurio, and U. M. Wewer A Role for ADAM12 in Breast Tumor Progression and Stromal Cell Apoptosis Cancer Res., June 1, 2005; 65(11): 4754 - 4761. [Abstract] [Full Text] [PDF]